A330350 Stock Overview
Engages in the production and sale of pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
WITHUS PHARMACEUTICAL Co.,LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,300.00 |
| 52 Week High | ₩9,280.00 |
| 52 Week Low | ₩5,610.00 |
| Beta | 0.72 |
| 1 Month Change | 0.16% |
| 3 Month Change | -10.64% |
| 1 Year Change | -20.55% |
| 3 Year Change | -37.93% |
| 5 Year Change | n/a |
| Change since IPO | -72.53% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well
Nov 13
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Shareholder Returns
| A330350 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 5.5% | -0.4% | -1.0% |
| 1Y | -20.6% | -1.6% | -11.5% |
Return vs Industry: A330350 underperformed the KR Pharmaceuticals industry which returned -1.6% over the past year.
Return vs Market: A330350 underperformed the KR Market which returned -11.5% over the past year.
Price Volatility
| A330350 volatility | |
|---|---|
| A330350 Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.5% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A330350 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A330350's weekly volatility (3%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | n/a | www.withuspharm.com |
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products.
WITHUS PHARMACEUTICAL Co.,LTD. Fundamentals Summary
| A330350 fundamental statistics | |
|---|---|
| Market cap | ₩83.17b |
| Earnings (TTM) | ₩4.78b |
| Revenue (TTM) | ₩102.72b |
17.4x
P/E Ratio0.8x
P/S RatioIs A330350 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A330350 income statement (TTM) | |
|---|---|
| Revenue | ₩102.72b |
| Cost of Revenue | ₩37.17b |
| Gross Profit | ₩65.55b |
| Other Expenses | ₩60.77b |
| Earnings | ₩4.78b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 362.42 |
| Gross Margin | 63.82% |
| Net Profit Margin | 4.66% |
| Debt/Equity Ratio | 25.4% |
How did A330350 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 17:07 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WITHUS PHARMACEUTICAL Co.,LTD. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jongsun Park | Eugene Investment & Securities Co Ltd. |
| Hyun Dong Lee | NH Investment & Securities Co., Ltd. |
| Kwan Jun Ra | NH Investment & Securities Co., Ltd. |